Biotech 2050 Podcast
Episodes
Leadership in revolutionizing cancer immunotherapy, Garo Armen, Ph.D., Chairman & CEO, Agenus
19 Apr 2023
Contributed by Lukas
Synopsis: Garo Armen, Ph.D., is the Chairman and CEO of Agenus, an immuno-oncology company with the goal of treating cancers with novel combinations ...
Revolutionizing brain health: CNS innovations, AI & more, Craig Thompson, CEO, Cerevance
12 Apr 2023
Contributed by Lukas
Synopsis: Craig Thompson is the CEO of Cerevance, a clinical-stage drug discovery and development company focused on developing novel therapeutics f...
Mental health: psychedelics & beyond, Florian Brand, CEO, & Srinivas Rao, CSO, atai Life Sciences
05 Apr 2023
Contributed by Lukas
Synopsis: We recorded this episode in December 2022 with Florian Brand and Srinivas Rao, the Co-Founders and CEO & CSO, respectively, of atai Life S...
High-impact oral small molecule therapy in autoimmune disease, Kevin Judice,Co-Founder & CEO,DICE Tx
29 Mar 2023
Contributed by Lukas
Synopsis: Kevin Judice is the Co-Founder and CEO of DICE Therapeutics, a clinical-stage biopharmaceutical company developing transformative medicine...
A new vision in inflammatory disease: RNAseq led precision medicine, Tariq Kassum, CEO, Celsius Tx
22 Mar 2023
Contributed by Lukas
Synopsis: Tariq Kassum, M.D. is the CEO of Celsius Therapeutics, a company pioneering new precision medicines in inflammatory disease by harnessing ...
Pioneering therapeutics targeting cellular stress pathways, Prakash Raman, President & CEO, Ribon Tx
15 Mar 2023
Contributed by Lukas
Synopsis: Prakash Raman, Ph.D., is the President and CEO of Ribon Therapeutics, a clinical stage biopharmaceutical company pursuing the development o...
Novel viral vectors in gene therapy, Joel Schneider, CEO & Robert Kotin, Founder, Carbon Biosciences
08 Mar 2023
Contributed by Lukas
Synopsis: Joel Schneider, Ph.D. and Robert Kotin, Ph.D. are the President & CEO and Founder & Chief Technology Advisor, respectively, of Carbon Biosc...
Advancing medicines that matter, Matt Gline, CEO, Roivant Sciences
01 Mar 2023
Contributed by Lukas
Synopsis: Matt Gline is the CEO of Roivant Sciences, a company that delivers innovative medicines and technologies to patients by building Vants – ...
Transforming chemotherapy for better patient outcomes, Jack Bailey, CEO, G1 Therapeutics
22 Feb 2023
Contributed by Lukas
Synopsis: Jack Bailey is the CEO of G1 Therapeutics, a commercial-stage biopharmaceutical company focused on the discovery, development and delivery ...
Personalized regenerative medicines, Nabiha Saklayen, PhD, Co-Founder & CEO, Cellino
15 Feb 2023
Contributed by Lukas
Synopsis: Nabiha Saklayen, PhD, is the Co-Founder and CEO of Cellino Biotech, a company working to democratize access to personalized stem cell-based...
Engaging the immune system against disease, Andrew Allen, Co-Founder, President & CEO, Gritstone bio
08 Feb 2023
Contributed by Lukas
Synopsis: Andrew Allen is the Co-Founder, President and CEO of Gritstone bio, a clinical-stage biotech company developing groundbreaking immunothera...
Novel approach to targeted protein degradation, Nicki Thompson, CEO, Amphista Therapeutics
01 Feb 2023
Contributed by Lukas
Synopsis: Nicki Thompson is the CEO of Amphista Therapeutics, a company identifying and advancing novel approaches in targeted protein degradation to...
Envisioning people focused clinical trials, Michael Rosenblatt, VP of Clinical Operations, Roche
25 Jan 2023
Contributed by Lukas
Disclaimer: Anything that is express in the following conversation are Michael's views and not necessarily those of Roche / Genentech. Synopsis: Mi...
Power of RNA to restore healthy gene expression, Josh Mandel-Brehm, President & CEO, CAMP4 Tx
18 Jan 2023
Contributed by Lukas
Synopsis: Josh Mandel-Brehm is the President and CEO of CAMP4 Therapeutics, a company pioneering mRNA amplification by using programmable ASO therape...
JPM23 Special: Rare diseases, Eslie Dennis, Kyowa Kirin, Arthur Suckow, DTx, & James Mackay, Aristea
11 Jan 2023
Contributed by Lukas
Synopsis: This special episode features a panel discussion with three biotech leaders about drug development for rare diseases. James Mackay, Ph.D.,...
JPM23 Special: Redefining cystic fibrosis treatment, Mike Cloonan, Pres. & CEO, Sionna Tx
10 Jan 2023
Contributed by Lukas
Synopsis: Mike Cloonan is the President and CEO of Sionna Therapeutics, a life sciences company dedicated to developing therapies for people living ...
JPM23 Special: Advancing RNA Therapeutics, Geoff Nosrati, CBO, Nutcracker Therapeutics
09 Jan 2023
Contributed by Lukas
Synopsis: Geoff Nosrati is the Chief Business Officer of Nutcracker Therapeutics, an early-stage company that is pioneering a revolutionary therapeu...
133. Pharma & Profits, John LaMattina, former Pres. of R&D, Pfizer, Senior Partner, PureTech Health
04 Jan 2023
Contributed by Lukas
Synopsis: John LaMattina is the former President of Global R&D at Pfizer and is currently a Senior Partner at PureTech Health. A self-proclaimed def...
132. Targeting ferroptosis cell death for cancer and beyond, Luba Greenwood, CEO, Kojin Therapeutics
21 Dec 2022
Contributed by Lukas
Synopsis: Luba Greenwood is the CEO of Kojin Therapeutics and Managing Partner of Dana Farber Cancer Institute Venture Fund. Kojin Therapeutics harne...
131. Epigenetic approaches to rare diseases, Amber Salzman, CEO, Epic Bio
14 Dec 2022
Contributed by Lukas
Synopsis: Amber Salzman is the CEO of Epic Bio, a company that develops therapies to dynamically control gene expression and treat complex diseases. ...
130. Breast cancer: targeted treatment options, Sean Bohen, President & CEO, Olema Oncology
07 Dec 2022
Contributed by Lukas
Synopsis: Sean Bohen is the President and CEO of Olema Oncology, a company dedicated to developing targeted therapies for women with breast cancer. ...
129. Progress in complex diseases: NASH, Long COVID, and beyond, Bill Hinshaw, Pres. & CEO, Axcella
30 Nov 2022
Contributed by Lukas
Synopsis: Bill Hinshaw is the President and CEO of Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat c...
128. Treating rare neurological diseases & guiding mission, Jeremy Levin, Chairman & CEO, Ovid Tx
23 Nov 2022
Contributed by Lukas
Synopsis: Jeremy Levin is the Chairman and CEO of Ovid Therapeutics, a company that develops medicines to treat patients with rare neurological condi...
127. Immuno-oncology landscape, Keith Flaherty, Dir. of Clin. Research, Mass General Cancer Center
16 Nov 2022
Contributed by Lukas
Synopsis: Keith Flaherty is the Director of Clinical Research at Mass General Cancer Center and a Professor of Medicine at Harvard Medical School. Dr...
126. New frontier in biology: harnessing the power of the repeatome, Dennis Zaller, CSO, ROME tx
09 Nov 2022
Contributed by Lukas
Synopsis: Dennis Zaller is the Chief Scientific Officer of ROME Therapeutics, a company developing novel therapies for cancer and autoimmune diseases...
125. Gene circuits for smarter medicine, Tim Lu, Co-Founder & CEO, & Kanya Rajangam, CMDO, Senti Bio
02 Nov 2022
Contributed by Lukas
Synopsis: This episode is co-hosted by Chris Ghadban at BIOS Builders. Guests Tim Lu and Kanya Rajangam are the Co-Founder & CEO and Chief Medical a...
124. Leukemia and beyond: Next-gen precision cell therapy, Ivan Dimov, Co-Founder & CEO, Orca Bio
26 Oct 2022
Contributed by Lukas
Synopsis: Ivan Dimov is the Co-Founder and CEO of Orca Bio, a cell therapy company focusing on next-generation precision cell therapies for blood can...
123. Nano-rare patients & rare diseases, Stanley Crooke, Founder & CEO, n-Lorem Foundation
19 Oct 2022
Contributed by Lukas
Synopsis: Stanley Crooke is Founder and CEO of n-Lorem Foundation, a nonprofit with the goal of discovering, developing and providing experimental AS...
122. New vision for cell & gene therapy, Andrew Sandford & Michael Paglia, ElevateBio BaseCamp
12 Oct 2022
Contributed by Lukas
Synopsis: Andrew Sandford and Michael Paglia are the President and COO, respectively, of ElevateBio BaseCamp, a cell and gene therapy technology com...
121. Mission-driven biotech investing, Josh Wolfe, Co-founder & Managing Partner, Lux Capital
05 Oct 2022
Contributed by Lukas
Synopsis: Josh Wolfe is the Co-Founder and Managing Partner of Lux Capital, a venture capital firm that invests in emerging science and technology ve...
120. Beyond CD8 immuno-oncology, Amanda Wagner, President and CEO, Immunitas Therapeutics
28 Sep 2022
Contributed by Lukas
Amanda Wagner is the President and CEO of Immunitas and was a founding member of the company at its launch in 2019. During her time at Immunitas, she ...
119. Special Edition: Quiet Leader, Loud Results, Ankit Mahadevia, Author
21 Sep 2022
Contributed by Lukas
Interested in purchasing the book? Order here: https://amzn.to/3R4RWfT Ankit Mahadevia is the founder and CEO of Spero Therapeutics, an organization ...
118. One team, one mission: tackling pruritus, Chris Posner, President & CEO, Cara Therapeutics
14 Sep 2022
Contributed by Lukas
Christopher Posner Chief Executive Officer, President, and Director Mr. Posner has served as our President and Chief Executive Officer since November...
117. Pioneering cell biology drug discovery, Rachel Meyers, CSO, Faze Medicines
31 Aug 2022
Contributed by Lukas
Rachel Meyers serves as the chief scientific officer at Faze Medicines. She was most recently an entrepreneur-in-residence at Third Rock Ventures (TR...
116. Retinal restoration and visions for growth, Brian Culley, CEO, Lineage Cell Therapeutics
24 Aug 2022
Contributed by Lukas
Mr. Culley joined Lineage as Chief Executive Officer in September 2018. Prior to joining Lineage, Mr. Culley served from August 2017 to September 2018...
115. Innovations in diabetes therapies, Timothy Kieffer, CSO, Manasi Sinha Jaiman, CMO, ViaCyte
17 Aug 2022
Contributed by Lukas
Timothy Kieffer Dr. Kieffer has a deep knowledge of gene and cell therapies, regenerative medicine, diabetes applied research, and industry experience...
114. Advancing cell therapy and multiple myeloma treatment, Ying Huang, CEO, Legend Biotech
10 Aug 2022
Contributed by Lukas
Dr. Ying Huang currently serves as Chief Executive Officer of Legend Biotech. He sits on the Board of Directors of Legend, as well as Quanta Therapeut...
113. Envisioning VDC cancer treatment, Elisabet de los Pinos, CEO, Aura Biosciences
03 Aug 2022
Contributed by Lukas
Eli de los Pinos is the founding CEO of Aura, which she has created from the ground up: She developed the company concept and has spearheaded fundrais...
112. New approaches in CNS diseases, Brad Margus, Co-founder and Executive Chairman, Cerevance
27 Jul 2022
Contributed by Lukas
Brad Margus is co-founder and Executive Chairman of Cerevance, a drug discovery company advancing a robust pipeline of targeted treatments for patient...
111. Synthetic biology & probiotics, Aoife Brennan, President & CEO, Synlogic
20 Jul 2022
Contributed by Lukas
Dr. Aoife Brennan is an experienced physician scientist and drug developer responsible for the successful clinical development and registration of mul...
110. Novel cell and gene therapies, Mark Gergen, CEO, Poseida Therapeutics, Inc.
13 Jul 2022
Contributed by Lukas
Mr. Gergen was appointed Chief Executive Officer of Poseida in February 2022. He joined Poseida in February 2018, initially serving as Chief Business ...
109. Gene therapy CDMO, Tim Miller, CEO, Erandi De Silva, SVP of Prod. Dev., Forge Biologics
29 Jun 2022
Contributed by Lukas
Timothy J. Miller, Ph.D. CEO, President and Co-Founder Timothy Miller is CEO, President and Co-Founder of Forge Biologics, Inc., a VC-backed gene the...
108. Vibe Bio launches to transform drug development, Alok Tayi Ph.D. and Susanna Harris Ph.D.
22 Jun 2022
Contributed by Lukas
Our guest this week is one of our hosts, Alok Tayi, and he has some exciting news. The official launch of his new company, Vibe Biotechnology, buildi...
107. Fighting infectious diseases with biologics, Paul Garofolo, Co-founder & CEO, Locus Biosciences
15 Jun 2022
Contributed by Lukas
Paul is the CEO & Co-founder of Locus Biosciences. With a career that spans manufacturing, research & development, information technology and corporat...
106. Next-Gen CRISPR applications, Trevor Martin, Co-founder & CEO, Mammoth Biosciences
08 Jun 2022
Contributed by Lukas
Dr. Trevor Martin founded Mammoth Biosciences with the mission to enable the next generation of CRISPR-based synthetic biology products across therape...
105. Gene therapy in hearing loss, Laurence Reid, PhD, CEO, Decibel Therapeutics
01 Jun 2022
Contributed by Lukas
Laurence joined Decibel in January 2020. He previously served as an entrepreneur in residence at Third Rock Ventures, where he focused on novel drug d...
104. Embracing nerve repair, Karen Zaderej, CEO, Chairman, and President, Axogen
25 May 2022
Contributed by Lukas
Ms. Zaderej has served as Axogen’s President, Chief Executive Officer, and a member of our Board of Directors since September 2011 and the Chairman ...
103. Patient-driven thrombosis innovations, John Glasspool, CEO, Anthos Therapeutics
18 May 2022
Contributed by Lukas
John Glasspool is CEO and member of the Board of Directors of Anthos Therapeutics. Mr. Glasspool is also a member of the Board of Directors of Dalcor...
102. Vanquishing Parkinson's Disease, Jim Sullivan, PhD, Co-founder & CEO, Vanqua Bio
11 May 2022
Contributed by Lukas
Dr. Sullivan is co-founder and CEO of Vanqua. In addition, he has been a Venture Partner with Orbimed since January 2019. Previously, he was the Vice ...
101. Revolutionizing genetic medicine, Paula Soteropoulos, Chairman of the Board, Ensoma
04 May 2022
Contributed by Lukas
Paula Soteropoulos brings to Ensoma more than 30 years of experience in the biopharma industry in areas of drug development, manufacturing, business d...
100. Disruptive forces in biotech, Jake Becraft, Lex Rovner, Josh Mandel-Brehm, & Nabiha Saklayen
27 Apr 2022
Contributed by Lukas
Jake Becraft is co-founder and CEO of Strand Therapeutics, an emerging biotechnology company at the forefront of mRNA therapeutics. With colleagues at...
99. Precision medicine for sepsis, Tim Sweeney, Co-Founder and CEO, Inflammatix, Inc.
20 Apr 2022
Contributed by Lukas
Tim Sweeney, MD, PhD, is co-founder and CEO of Inflammatix. Tim has extensive experience in medical practice (general & trauma surgery), bench researc...
98. Brain health disorders, Al Robichaud, Ph.D., CSO, Sage Therapeutics
13 Apr 2022
Contributed by Lukas
Al leads teams in early-stage discovery up through non-clinical development, identifying new drug candidates for advancement into clinical research. A...
97. Patient driven treatments in rare diseases, Stuart Peltz, Founder & CEO, PTC Therapeutics
06 Apr 2022
Contributed by Lukas
Dr. Stuart Peltz founded PTC Therapeutics in 1998 and has served as Chief Executive Officer and a member of the Board of Directors since the company’...
96. Obesity & rare disease, Patrick Kleyn, SVP and Head of Translational R&D,Rhythm Pharmaceuticals
30 Mar 2022
Contributed by Lukas
Patrick Kleyn joined Rhythm in 2018 with over 25 years’ experience in human genetics and genomics, and he was named as head of TRAD in 2021. Prior t...
95. Gene writing, Dr. Jake Rubens, Co-Founder & CIO, Hari Pujar, COO, Tessera Therapeutics
23 Mar 2022
Contributed by Lukas
Jacob(Jake)Rubens, Co-Founder, Chief Innovation Officer Jake is Co-Founder and Chief Innovation Officer of Tessera Therapeutics, as well as a Princip...
94. Cell therapy in a war on cancer, Kleanthis Xanthopoulos, Co-Founder & CEO, Shoreline Biosciences
16 Mar 2022
Contributed by Lukas
Kleanthis is a serial biotechnology entrepreneur with over two decades of experience in the biotechnology and pharmaceutical research industries as an...
93. Human-centric data and AI for improved drug development, David Berry, Founder & CEO, Valo Health
09 Mar 2022
Contributed by Lukas
David Berry is the Founder and CEO of Valo and since 2005, has served as General Partner at Flagship Pioneering, having founded over 25 companies incl...
92. Software driven biology for small molecule mRNA drugs, Yochi Slonim, Co-founder & CEO, Anima
02 Mar 2022
Contributed by Lukas
A serial entrepreneur in software and biotech, Yochi Slonim has built multiple companies as a founder and CEO through all phases of growth all the way...
91. tRNA therapies, Lovisa Afzelius, Founding CEO, Theonie Anastassiadis, Co-founder & CIO, Alltrna
23 Feb 2022
Contributed by Lukas
Lovisa Afzelius is an origination partner at Flagship Pioneering and the former SVP of Strategy & Operations at Flagship-founded Cogen Immune Medicine...
90. From pharma to founding a biotech, James Mackay, Founder, President & CEO, Aristea Therapeutics
16 Feb 2022
Contributed by Lukas
James Mackay, PhD, Founder, President and Chief Executive Officer, has over 25 years of development and commercialization expertise in the pharmaceuti...
89. Regenerative medicine pioneer, Laura Niklason, Founder, President, & CEO, Humacyte, Inc.
09 Feb 2022
Contributed by Lukas
A physician-scientist, her groundbreaking work in vascular and lung engineering has made Dr. Niklason a world leader in regenerative medicine. She is ...
88. Biologics in autoimmune and kidney disease, Marshall Fordyce, CEO and Founder, Vera Therapeutics
02 Feb 2022
Contributed by Lukas
Dr. Fordyce brings more than 15 years’ experience leading teams in drug discovery, development, clinical translation, and commercialization of new t...
87. Patient-centric Duchenne gene therapy, Joel Schneider, COO, Solid Biosciences
26 Jan 2022
Contributed by Lukas
Dr. Schneider is the Chief Operating Officer for Solid Biosciences, responsible for overseeing corporate and technical operations, quality, patient ad...
86. Resilient to the core, Trish Hurter, CEO, Jess Ballinger, President & COO, Lyndra Therapeutics
19 Jan 2022
Contributed by Lukas
Patricia (Trish) Hurter, Dr. Patricia Hurter is CEO of Lyndra Therapeutics. Prior to Lyndra, Dr. Hurter was Senior Vice President of Pharmaceutical a...
85. Genomic testing for precision oncology, Shawn Leland, Founder and CEO, Elevation Oncology
12 Jan 2022
Contributed by Lukas
Shawn M. Leland is the Founder and Chief Executive Officer of Elevation Oncology overseeing all day-to-day operations. Shawn brings over a decade of e...
84. Leadership insights, Paul Biondi, President, Pioneering Medicines,Flagship Pioneering initiative
05 Jan 2022
Contributed by Lukas
Paul Biondi, Executive Partner, Flagship Pioneering and President, Pioneering Medicines Paul joined Flagship Pioneering in 2019 as Executive Partner,...
83. Season 2 Wrap Up, Rahul Chaturvedi and Alok Tayi
15 Dec 2021
Contributed by Lukas
Thank you for your support for Season 2! We reflect and look forward to Season 3 on this episode! Learn more about our co-hosts below! Alok Tayi, PhD...
82. RNA therapeutics for neurological indications, Barry Ticho, CMO, Stoke Therapeutics
08 Dec 2021
Contributed by Lukas
As Chief Medical Officer Dr. Ticho is responsible for Stoke’s efforts to develop first-in-class RNA based disease-modifying medicines to treat sever...
81. Innovations for narcolepsy, Greg Divis, CEO, Avadel Pharmaceuticals
01 Dec 2021
Contributed by Lukas
Gregory J. Divis serves as Avadel’s Chief Executive Officer and a member of Avadel’s Board of Directors. Greg was appointed CEO in June of 2019, a...
80. Targeted cancer immunotherapies, Chip Clark, President and CEO, Genocea
17 Nov 2021
Contributed by Lukas
Chip has served as Genocea's President and Chief Executive Officer since February 2011 after serving as Chief Business Officer from August 2010 to Feb...
79. Leadership in rare diseases, Srini Ramanathan, SVP, R&D Sciences, Horizon Therapeutics
10 Nov 2021
Contributed by Lukas
Srini Ramanathan, Ph.D., Senior Vice President, Research and Development Sciences Srini Ramanathan, Ph.D., joined Horizon Therapeutics in 2018. He le...
78. Translating lab insights for outcomes to cancer patients, Heike Keilhack, CSO,Ribon Therapeutics
03 Nov 2021
Contributed by Lukas
Dr. Keilhack is an accomplished cancer biologist with rich experience in cell biology, animal models of cancer, pharmacology and translational medicin...
77. Battling rare diseases: patients and scientists, Ethan Perlstein, Founder and CEO, Perlara
27 Oct 2021
Contributed by Lukas
Dr. Ethan Perlstein is the founder and CEO of Perlara PBC, the first biotech public benefit company established in 2014 that partners with highly moti...
76. Advancing immuno-oncology, Michel Detheux, President and CEO, iTeos Therapeutics
20 Oct 2021
Contributed by Lukas
Michel Detheux is the co-founder, President, and CEO of iTeos Therapeutics, and has held the role of CEO since the company’s inception in 2012. He p...
75. Innovations in cell therapies via microfluidics, Armon Sharei, CEO and Founder, SQZ Biotech
13 Oct 2021
Contributed by Lukas
Armon Sharei, PhD, is the Chief Executive Officer and Founder of SQZ Biotechnologies, a clinical-stage biotechnology company focused on unlocking the ...
74. Pioneering circular oRNA therapeutics, Thomas Barnes, Chief Executive Officer, Orna Therapeutics
06 Oct 2021
Contributed by Lukas
Thomas is a veteran entrepreneur who has turned creative scientific visions into successful businesses for both startups and established organizations...
73. Patient focused gene editing for heart disease, Andrew Bellinger, CSO/CMO, Verve Therapeutics
29 Sep 2021
Contributed by Lukas
Andrew Bellinger is chief scientific officer of Verve Therapeutics. He is a general cardiologist at Brigham and Women’s Hospital and is board-certif...
72. Unlocking biologic drug production, Brian Finrow, Co-Founder and CEO, Lumen Bioscience
22 Sep 2021
Contributed by Lukas
Brian Finrow brings the skills and experience of a lawyer to a position that, in the biotech world, is more typically occupied by a scientist. This is...
71. Leadership in immuno-oncology, Jeffrey Goldberg, President and CEO, Immunitas Therapeutics
15 Sep 2021
Contributed by Lukas
Jeffrey Goldberg is the president and CEO of Immunitas. Jeff is an experienced biotech program and brand leader with over 20 years of industry experie...
70. Modern treatments for psoriasis and atopic dermatitis, Todd Zavodnick, CEO, Dermavant Sciences
25 Aug 2021
Contributed by Lukas
Todd Zavodnick has over 20 years of leadership experience in the biopharmaceutical industry. Prior to joining Dermavant in November 2018, Mr. Zavodnic...
69. Antibodies in immuno-oncology, Alison O'Neill, Chief Medical Officer, Surface Oncology
18 Aug 2021
Contributed by Lukas
Alison serves as the chief medical officer at Surface Oncology. She has over 20 years of experience in clinical research, oncology drug development an...
68. Patient-focused Wet AMD, Nancy Lurker, President & CEO, Said Saim, CTO, EyePoint Pharmaceuticals
11 Aug 2021
Contributed by Lukas
Nancy Lurker: President & Chief Executive Officer Our President, CEO, and a director since September 2016, Ms Lurker has broad-ranging experience in t...
67. ML protein therapy, Mike Nally, CEO, and Geoff von Maltzahn, Co-Founder, Generate Biomedicines
04 Aug 2021
Contributed by Lukas
Mike Nally is the Chief Executive Officer of Generate Biomedicines and a CEO-Partner at Flagship Pioneering. Mike brings significant experience leadin...
66. I’ll take “Wild Rides” for 500, Alex: Biotech Entrepreneur’s Story, Ron Cohen, CEO, Acorda
28 Jul 2021
Contributed by Lukas
Ron Cohen, M.D. is President, CEO and founder of Acorda Therapeutics, Inc., a public biotechnology company developing therapies for disorders of the n...
65. Patient focused precision oncology, Avanish Vellanki, Cofounder and CEO, Rain Therapeutics
21 Jul 2021
Contributed by Lukas
Avanish Vellanki is passionate about offering cancer patients better treatment options, and he firmly believes that precision oncology strategies are ...
64. Tech-driven acceleration in clinical trials, Benjamine Liu, Co-founder and CEO, TrialSpark
14 Jul 2021
Contributed by Lukas
Benjamine Liu is the co-founder and CEO of TrialSpark, a technology company that is reimagining drug development. Benjamine received his DPhil at Oxf...
63. Building a leader in infectious diseases, Ankit Mahadevia, President and CEO, Spero Therapeutics
07 Jul 2021
Contributed by Lukas
Ankit Mahadevia is the CEO of Spero Therapeutics and a member of the Board of Directors. He was formerly a Venture Partner in the life sciences group ...
62. Tackling autoimmune and allergic disease, Jonathan Rigby, Group CEO, Revolo Biotherapeutics
23 Jun 2021
Contributed by Lukas
Jonathan Rigby is an experienced CEO with three decades of experience creating value and opportunities for companies in the pharmaceutical, biotech an...
61. Groundbreaking immunology microbe oral therapies, Simba Gill, CEO, Evelo Biosciences
16 Jun 2021
Contributed by Lukas
Balkrishan (Simba) Gill, Ph.D. has served as our President, Chief Executive Officer and a member of our Board of Directors since September 2015. Dr. G...
60. BIOS Edition: Investing in biotech and healthcare, Yizhen Dong, Partner, Global Founders Capital
09 Jun 2021
Contributed by Lukas
Yizhen is passionate about investing in and working with persevering entrepreneurs who want to change the world, especially in healthcare and biotech....
59. Targeted cancer therapies using engineered viruses, Alice Bexon, Chief Medical Officer, Vyriad
19 May 2021
Contributed by Lukas
Dr. Bexon brings to Vyriad more than 20 years of management experience in clinical development of biopharmaceuticals, including management of multi-si...
58. End game vaccine for COVID-19, Marty Moore, Cofounder and CEO, Meissa Vaccines
12 May 2021
Contributed by Lukas
Martin (Marty) is a cofounder and chief executive officer of Meissa Vaccines. Prior to cofounding Meissa, Marty was an Associate Professor at Emory Un...
57. Next frontier in schizophrenia and mental health, Andrew Miller, Founder and COO, Karuna
05 May 2021
Contributed by Lukas
Dr. Miller is a Founder and the Chief Operating Officer of Karuna Therapeutics. Dr. Miller is the lead inventor of Karuna’s KarXT platform and serve...
56. Turning cancer on itself, Sam Mazin, Founder and CTO, Thorsten Melcher, CBO, RefleXion
28 Apr 2021
Contributed by Lukas
Samuel Mazin, Ph.D. Founder and Chief Technology Officer Member, Board of Directors Sam Mazin, Ph.D., co-founded RefleXion Medical in 2009, where he ...
55. Gene therapy for hearing loss, Heather Wolff, VP of Clinical Development Operations, Decibel
21 Apr 2021
Contributed by Lukas
Heather Wolff joined Decibel in February 2018 as the head of clinical development operations for Decibel Therapeutics. Heather is responsible for Deci...
54. CRISPR treating cancer, Rachel Haurwitz, Co-founder and CEO, Caribou Biosciences
14 Apr 2021
Contributed by Lukas
Rachel is a co-founder of Caribou Biosciences and has been President and CEO since its inception in 2011. Rachel is an inventor on several patents and...
53. Leading a rare disease biopharma company, Paula Ragan, CEO and President, X4 Pharmaceuticals
08 Apr 2021
Contributed by Lukas
Dr. Ragan has been X4’s President and Chief Executive Officer and a member of the X4 Board of Directors since July 2014. She has more than 18 years ...
52. SPACs and infectious disease past and future, Joe Hernandez, CEO, Blue Water Acquisition Corp.
31 Mar 2021
Contributed by Lukas
Joseph Hernandez is an established leader in biotech entrepreneurship and early-stage technology development. With a strong background in biology, epi...
51. Pioneering innovations for neurological indications, Chris Wright, CMO, Cyclerion
25 Mar 2021
Contributed by Lukas
Chief Medical Officer, Christopher Wright, MD, PhD, is a neurologist and neuroscientist who brings two decades of medical research and drug developmen...